New GLP-1; Semaglutide (Ozempic)
US$ 27.48
glp 1 and appetite Gut Hormones Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity Health Feed - Glp-1 Drugs
Description
The perioperative management of patients using glucagon-like peptide 1 receptor agonists remains a topic of debate
How to adapt healthy eating strategies with GLP-1 medications for long-term success along with dietary strategies for managing side effects.
doi: 10.3389/fcimb.2020.588517
To stay ahead of this shifting environment, pharma companies should consider the following imperatives: Massive patient drop-off undermines obesity GLP-1 uptake: Despite strong demand, only 10% of obesity patients persist with therapy after one year
Vanessa Mack (Dean)
Image Credit: Visual Capitalist Data: S&P global, GLP-1 Men, Financial times, IFEBP & Reuters #biotech #biopharma #GLP1 #obesity | 14 comments on LinkedIn
